Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZS CVE:HEM CVE:IBT NYSE:MBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.60+2.2%$3.66$3.96▼$12.00$6.45M1.557,305 shs1,332 shsHEMHemostemixC$0.08+6.7%C$0.13C$0.04▼C$0.43C$11.66M0.2387,993 shs380,062 shsIBTIBEX TechnologiesC$1.44C$1.44C$0.75▼C$1.45C$35.54M-0.0568,888 shs200 shsMBXMBX Biosciences$12.16+9.3%$12.19$4.81▼$27.50$406.44MN/A326,110 shs690,201 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%-5.89%+2.42%+1.27%-41.45%HEMHemostemix0.00%-20.00%-42.86%-15.79%+60.00%IBTIBEX Technologies0.00%0.00%0.00%0.00%0.00%MBXMBX Biosciences0.00%-11.56%-6.75%+9.16%+1,215,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AN/AN/AN/AIBTIBEX TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.5375 of 5 stars3.50.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AHEMHemostemix 0.00N/AN/AN/AIBTIBEX Technologies 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.63209.42% UpsideCurrent Analyst Ratings BreakdownLatest HEM, MBX, IBT, and AEZS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.72N/AN/A$14.99 per share0.24HEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/AIBTIBEX TechnologiesC$5.77M6.15C$0.92 per share1.56C$0.58 per share2.48MBXMBX BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)HEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/AIBTIBEX TechnologiesC$3.10MC$0.1211.52∞N/A53.78%21.95%6.42%N/AMBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AIBTIBEX TechnologiesN/A3.11%N/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93HEMHemostemix-55.070.040.48IBTIBEX Technologies11.066.244.93MBXMBX BiosciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%HEMHemostemixN/AIBTIBEX Technologies19.05%MBXMBX BiosciencesN/AInsider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%HEMHemostemix10.43%IBTIBEX Technologies25.36%MBXMBX Biosciences52.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataHEMHemostemixN/A145.73 millionN/ANot OptionableIBTIBEX TechnologiesN/A24.68 millionN/ANot OptionableMBXMBX Biosciences3633.42 millionN/AN/AHEM, MBX, IBT, and AEZS HeadlinesRecent News About These CompaniesMBX Biosciences (NYSE:MBX) Earns Outperform Rating from Analysts at MizuhoAugust 8 at 2:25 AM | americanbankingnews.comMBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 7, 2025 | globenewswire.comMBX Biosciences (NYSE:MBX) Coverage Initiated at MizuhoAugust 6, 2025 | marketbeat.comMizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationAugust 5, 2025 | msn.comTD Asset Management Inc Raises Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)August 5, 2025 | marketbeat.comMBX Biosciences Inc. (MBX) Stock Price Today - WSJAugust 2, 2025 | wsj.comMBX Biosciences (NYSE:MBX) Shares Up 15.7% - What's Next?July 26, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Receives Average Rating of "Buy" from AnalystsJuly 19, 2025 | marketbeat.comOppenheimer Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationJuly 17, 2025 | msn.comOppenheimer Initiates Coverage on MBX Biosciences (NYSE:MBX)July 16, 2025 | marketbeat.comMBX Biosciences Inc Executives - MorningstarJune 25, 2025 | morningstar.comMMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - MorningstarJune 24, 2025 | morningstar.comMMBX Biosciences Inc Chart - MorningstarJune 24, 2025 | morningstar.comMMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical DevelopmentJune 23, 2025 | globenewswire.comMBX Biosciences Submits IND for Obesity TreatmentJune 16, 2025 | tipranks.comMBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of ObesityJune 16, 2025 | globenewswire.comMBX Biosciences to Present at the American Diabetes Association 85th Scientific SessionsJune 10, 2025 | globenewswire.commbx biosciences announces board changes and director electionsJune 7, 2025 | uk.investing.comMBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative BuyMay 31, 2025 | seekingalpha.comMBX Biosciences to Participate in June Investor ConferencesMay 20, 2025 | globenewswire.comMBX Biosciences, Inc.: Strong Buy Rating Amid Promising Phase II Data and Robust Financial PositionMay 13, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks Powering the Next Tech RevolutionBy Ryan Hasson | August 8, 2025View 3 AI Infrastructure Stocks Powering the Next Tech RevolutionThese 3 Undervalued Stocks Could Surge as Value Rotation NearsBy Gabriel Osorio-Mazilli | July 14, 2025View These 3 Undervalued Stocks Could Surge as Value Rotation NearsThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are BuyingBy Thomas Hughes | July 23, 2025View The Bottom Is in For These 3 Small-Cap Stocks Insiders Are BuyingSmart Investors Are Watching These 3 Undervalued StocksBy Gabriel Osorio-Mazilli | July 12, 2025View Smart Investors Are Watching These 3 Undervalued Stocks3 Stocks Every Value Investor Should Watch Out for Right NowBy Gabriel Osorio-Mazilli | August 4, 2025View 3 Stocks Every Value Investor Should Watch Out for Right NowHEM, MBX, IBT, and AEZS Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.60 +0.08 (+2.25%) As of 08/8/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Hemostemix CVE:HEMC$0.08 +0.01 (+6.67%) As of 08/8/2025 01:15 PM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.IBEX Technologies CVE:IBTC$1.44 0.00 (0.00%) As of 04/5/2024IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.MBX Biosciences NYSE:MBX$12.16 +1.03 (+9.25%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$12.16 0.00 (-0.01%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale